Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
NIH Grants & Funding for Neurofibrosarcoma | Kisho | Kisho
2 additional grants classified as “Other” (multi-disciplinary, infrastructure, etc.).
Funding by Fiscal Year
NIH fiscal year (Oct–Sep)
$8.1M
FY22
$7.9M
FY23
$7.8M
FY24
$7.9M
FY25
$1.7M
FY26
By Funding Mechanism
R01
8
ZIA
3
F30
2
F99
1
K08
1
R00
1
Funding Gap Analysis
Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Neurofibrosarcoma. Strongest funded area: Basic Science. Largest gap: Epidemiology / Natural History.
Translational / Drug DevelopmentFunded, Few Publications
5 funded grants in Translational / Drug Development but only 1 related publication found for neurofibrosarcoma. This may indicate early-stage research that hasn't yet produced published results.
Epidemiology / Natural HistoryPublished, Not NIH-Funded
12 publications in Case Report / Case Series but no NIH-funded grants found in Epidemiology / Natural History for neurofibrosarcoma. Existing research activity suggests this may be a viable area for grant applications.
Adjacent Research(8 grants)
These grants mention Neurofibrosarcoma as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.
Other(8)
OtherU54Completed
Developmental and Hyperactive Ras Tumor (DHART) SPORE
Clapp, David et al.·INDIANA UNIVERSITY INDIANAPOLIS·INDIANAPOLIS, IN
